Gelesis announces initiation of a 6-month weight loss study with Gelesis100

The GLOW (Gelesis Loss Of Weight) study is a 6-month, randomized, double-blind, placebo-controlled, parallel-group study designed to further assess the effect of Gelesis100 on body weight and glycaemic control parameters in overweight and obese subjects, including pre-diabetics and type 2 diabetics.

Gelesis, a biotechnology company focused on the development of first-in-class therapeutics to induce weight loss and improve glycaemic control, announced today that it has initiated the GLOW study.

The GLOW study will assess the effect of repeated administration of Gelesis100 for 6 months on body weight and glycaemic control parameters in 168 overweight and obese patients, including pre-diabetics and type 2 diabetics. The study will be conducted in ten sites in Europe and the United States. The primary endpoints for the GLOW study are change in total body weight from baseline to end of randomised treatment and percentage of patients with at least 5% weight loss. The secondary endpoints include changes in key glycaemic control parameters.

'We designed the GLOW study to assess the safety and efficacy of Gelesis100 for a longer period of time on a broader patient population, including type 2 diabetics, as compared with the First Loss Of Weight (FLOW) study,' said Hassan Heshmati, CMO of Gelesis. 'We are eager to further build upon the FLOW study, which resulted in statistically significant weight loss during 3 months in overweight and obese patients.'

Gelesis is a clinical stage company focused on the development of novel therapies to induce weight loss and improve glycemic control in overweight and obese patients. The Gelesis executive and advisory team includes some of the world's leading experts in obesity research and clinical development, entrepreneurs, and innovators in advanced materials. Gelesis was co-founded by PureTech, a science and technology R&D company (www.gelesis.com).